نتائج البحث - David G Warnock

Current and Investigational Therapeutics for Fabry Disease حسب Andrew Felis, Michael Whitlow, Abigayle Kraus, David G. Warnock, Eric Wallace

احصل على النص الكامل

High-sensitivity C-reactive protein and risk of sepsis. حسب Henry E Wang, Nathan I Shapiro, Monika M Safford, Russell Griffin, Suzanne Judd, Joel B Rodgers, David G Warnock, Mary Cushman, George Howard

احصل على النص الكامل

Rapid Immunochromatographic Detection of Serum Anti-α-Galactosidase A Antibodies in Fabry Patients after Enzyme Replacement Therapy. حسب Sachie Nakano, Takahiro Tsukimura, Tadayasu Togawa, Toya Ohashi, Masahisa Kobayashi, Katsuyoshi Takayama, Yukuharu Kobayashi, Hiroshi Abiko, Masatsugu Satou, Tohru Nakahata, David G Warnock, Hitoshi Sakuraba, Futoshi Shibasaki

احصل على النص الكامل

A new approach to identifying patients with elevated risk for Fabry disease using a machine learning algorithm حسب John L. Jefferies, Alison K. Spencer, Heather A. Lau, Matthew W. Nelson, Joseph D. Giuliano, Joseph W. Zabinski, Costas Boussios, Gary Curhan, Richard E. Gliklich, David G. Warnock

احصل على النص الكامل

A distinct urinary biomarker pattern characteristic of female Fabry patients that mirrors response to enzyme replacement therapy. حسب Andreas D Kistler, Justyna Siwy, Frank Breunig, Praveen Jeevaratnam, Alexander Scherl, William Mullen, David G Warnock, Christoph Wanner, Derralynn A Hughes, Harald Mischak, Rudolf P Wüthrich, Andreas L Serra

احصل على النص الكامل

Chronic Kidney Disease: A Public Health Problem That Needs a Public Health Action Plan حسب Anton C. Schoolwerth, MD, MSHA, Michael M. Engelgau, MD, Thomas H. Hostetter, MD, Kathy H. Rufo, MPH, Dolph Chianchiano, JD, MPA, William M. McClellan, MD, MPH, David G. Warnock, MD, Frank Vinicor, MD

احصل على النص الكامل

Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label ex... حسب Myrl Holida, Aleš Linhart, Nicola Longo, Eric Wallace, Camilla Tøndel, Derralynn Hughes, David G. Warnock, Antonio Pisani, François Eyskens, Patrick Deegan, Ulla Feldt-Rasmussen, Ozlem Goker-Alpan, Ankit Mehta, Giovanni Piotti, Vito Fichera, Meng Wang, Raul Chertkoff, Stephen Waldek, William R. Wilcox, John A. Bernat

احصل على النص الكامل

Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase. حسب David G Warnock, Daniel G Bichet, Myrl Holida, Ozlem Goker-Alpan, Kathy Nicholls, Mark Thomas, Francois Eyskens, Suma Shankar, Mathews Adera, Sheela Sitaraman, Richie Khanna, John J Flanagan, Brandon A Wustman, Jay Barth, Carrolee Barlow, Kenneth J Valenzano, David J Lockhart, Pol Boudes, Franklin K Johnson

احصل على النص الكامل

Early indicators of disease progression in Fabry disease that may indicate the need for disease-specific treatment initiation: findings from the opinion-based PREDICT-FD modified D... حسب James C Moon, Albina Nowak, Derralynn A Hughes, Mark Thomas, Raphael Schiffmann, Ales Linhart, David G Warnock, Sandro Feriozzi, Patricio Aguiar, Patrick B Deegan, Fatih Ezgu, Andrea Frustaci, Olivier Lidove, Jean-Claude Lubanda, Kathleen Nicholls, Dau-Ming Niu, Uma Ramaswami, Ricardo Reisin, Paula Rozenfeld, Einar Svarstad, Roser Torra, Bojan Vujkovac, Michael L West, Jack Johnson, Mark J Rolfe

احصل على النص الكامل